Here, we have used a general strategy to assess the capability of two erythroid cell–enriched E3 ubiquitin ligases, TRIM10 and TRIM58, to degrade a POI, BCL11A, which is a validated target for reactivation of HbF in hemoglobin disorders. Here, BCL11A is linked to hemoglobinopathy.